Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children

NARecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

May 3, 2015

Primary Completion Date

May 3, 2026

Study Completion Date

July 3, 2028

Conditions
Focal Segmental Glomerulosclerosis
Interventions
DEVICE

LIPOSORBER® LA-15 System

LIPOSORBER® LA-15 System is an extracorporeal blood purification system. Approximately 3 to 4 L of plasma is treated in a single treatment session and it takes 2 to 3 hours. Recommended frequency of the treatment is twice weekly for 3 weeks followed by once weekly for 6 weeks, thus it takes 9 weeks for a total of 12 treatment sessions.

Trial Locations (12)

10065

RECRUITING

Weill Cornell Medical Center / NewYork-Presbyterian, New York

19134

RECRUITING

St. Christopher's Hospital for Children, Philadelphia

19803

RECRUITING

Nemours/A.I. duPont Hospital for Children, Wilmington

23219

WITHDRAWN

Children's Hospital of Richmond at VCU, Richmond

27599

RECRUITING

University of North Carolina, Chapel Hill

29425

RECRUITING

Medical University of South Carolina Children's Hospital, Charleston

32827

TERMINATED

Nemours Children's Health, Orlando

44308

RECRUITING

Akron Children's Hospital, Akron

49503

RECRUITING

Helen DeVos Children's Hospital, Grand Rapids

55454

RECRUITING

University of Minnesota, Minneapolis

90048

RECRUITING

Cedars Sinai Medical Center, Los Angeles

92354

RECRUITING

Loma Linda University Children's Hospital, Loma Linda

All Listed Sponsors
lead

Kaneka Medical America LLC

INDUSTRY